Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Oct;313(1):e240016.
doi: 10.1148/radiol.240016.

Meta-Analysis of Interobserver Agreement in Assessment of Interstitial Lung Disease Using High-Resolution CT

Affiliations
Meta-Analysis

Meta-Analysis of Interobserver Agreement in Assessment of Interstitial Lung Disease Using High-Resolution CT

Liam Delaney et al. Radiology. 2024 Oct.

Abstract

Background High-resolution CT (HRCT) is central to the assessment of interstitial lung disease (ILD), and accurate classification of disease has important implications for patients. Evaluation of imaging features can be challenging, even for experienced thoracic radiologists. Previous work has provided equivocal evidence on the interpretation of HRCT features at ILD-related imaging. Purpose To perform a meta-analysis to assess the level of agreement among expert thoracic radiologists in interpreting ILD-related imaging. Materials and Methods A systematic literature search from January 2000 to October 2023 of the Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases was performed for articles reporting assessments of interobserver agreement between thoracic radiologists for evaluation of ILD findings, such as severity and progression of disease, presence of features such as honeycombing and ground-glass opacification, and classification based on the 2011 and 2018 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Asociación Latinoamericana del Tórax (ATS/ERS/JRS/ALAT) guidelines for idiopathic pulmonary fibrosis (IPF). Meta-analysis was performed using a random-effects model to obtain pooled κ or intraclass correlation coefficient (ICC) values as measures of interobserver agreement. Results The final analysis included 13 studies consisting of 6943 images and 146 radiologists. In 10 studies assessing agreement of specific radiologic findings in ILD, the pooled κ value was 0.56 (95% CI: 0.43, 0.70). In eight studies, the assessed interobserver agreement of the ATS/ERS/JRS/ALAT diagnostic guidelines for IPF based on usual interstitial pneumonia (UIP) patterns, the pooled κ value was 0.61 (95% CI: 0.48, 0.74). One study reported a κ value of 0.87 for ILD progression. Seven studies assessing ILD severity could not be pooled; the individual κ values for ILD severity ranged from 0.64 to 0.90, and ICC values ranged from 0.63 to 0.96. Conclusion There was moderate agreement between thoracic radiologists when assessing ILD features and UIP pattern diagnosis but little evidence on agreement of disease severity, extent, or progression. Meta-analysis registry no. PROSPERO CRD42022361803 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Humbert in this issue.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest: L.D. No relevant relationships. S.A. Grant from Janssen; chair of the Training Committee of the British Society of Cardiovascular Imaging (unpaid). A.M. No relevant relationships. M.S. No relevant relationships. M.G. No relevant relationships. H.S. No relevant relationships. E.C. No relevant relationships. S.M. No relevant relationships. M.K. No relevant relationships. O.E. No relevant relationships. S.R. No relevant relationships. C.J. No relevant relationships. N.J.S. No relevant relationships. A.J.S. Grant from Janssen; consulting fees from Janssen; speaker fees from Janssen. K.D. Grants to institution from Wellcome Trust UK, National Institute of Health Research UK, and Janssen; support for attending meetings or travel from the Royal College of Radiologists; leadership or advisory role for the Royal College of Radiologists AI Committee and RADIANT.

Figures

None
Graphical abstract
Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or
PRISMA, flowchart. Ovid MEDLINE, Embase, and Cochrane Central Register of
Controlled Trials (CENTRAL) searches yielded 4658 results. The full texts of
266 studies were reviewed, including backward reference searching. Of the 70
studies eligible for inclusion in the systematic review, 13 provided
sufficient data for meta-analysis. AI = artificial intelligence, ILD =
interstitial lung disease.
Figure 1:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or PRISMA, flowchart. Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) searches yielded 4658 results. The full texts of 266 studies were reviewed, including backward reference searching. Of the 70 studies eligible for inclusion in the systematic review, 13 provided sufficient data for meta-analysis. AI = artificial intelligence, ILD = interstitial lung disease.
Forest plot for 10 studies assessing interobserver agreement of
specific disease patterns at high-resolution CT. The dotted line represents
the pooled κ using the three-level random-effects model; boxes
indicate the point estimate of the κ value for each study (study
weight represented by the size of the box); horizontal bars show the 95% CI
for each study; and the center of each diamond represents the overall pooled
κ, while the width of the diamond indicates the 95% CI.
Figure 2:
Forest plot for 10 studies assessing interobserver agreement of specific disease patterns at high-resolution CT. The dotted line represents the pooled κ using the three-level random-effects model; boxes indicate the point estimate of the κ value for each study (study weight represented by the size of the box); horizontal bars show the 95% CI for each study; and the center of each diamond represents the overall pooled κ, while the width of the diamond indicates the 95% CI.
Forest plot for studies assessing interobserver variability of the
2011 and 2018 American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Asociación Latinoamericana del
Tórax (ATS/ERS/JRS/ALAT) diagnostic guidelines for radiologic
features of usual interstitial pneumonia. Eight studies had sufficient data
to be included in either the 2011 or 2018 subgroup analysis or both. The
dotted line represents the pooled κ using the three-level
random-effects model; boxes indicate the point estimate of the κ
value for each study (study weight represented by the size of the box);
horizontal bars show the 95% CI for each study; and the center of each
diamond represents the overall pooled κ, while the width of the
diamond indicates the 95% CI.
Figure 3:
Forest plot for studies assessing interobserver variability of the 2011 and 2018 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Asociación Latinoamericana del Tórax (ATS/ERS/JRS/ALAT) diagnostic guidelines for radiologic features of usual interstitial pneumonia. Eight studies had sufficient data to be included in either the 2011 or 2018 subgroup analysis or both. The dotted line represents the pooled κ using the three-level random-effects model; boxes indicate the point estimate of the κ value for each study (study weight represented by the size of the box); horizontal bars show the 95% CI for each study; and the center of each diamond represents the overall pooled κ, while the width of the diamond indicates the 95% CI.

References

    1. Wijsenbeek M , Suzuki A , Maher TM . Interstitial lung diseases . Lancet 2022. ; 400 ( 10354 ): 769 – 786 . - PubMed
    1. Lederer DJ , Martinez FJ . Idiopathic pulmonary fibrosis . N Engl J Med 2018. ; 378 ( 19 ): 1811 – 1823 . - PubMed
    1. Distler O , Highland KB , Gahlemann M , et al . Nintedanib for systemic sclerosis-associated interstitial lung disease . N Engl J Med 2019. ; 380 ( 26 ): 2518 – 2528 . - PubMed
    1. Flaherty KR , Wells AU , Cottin V , et al . Nintedanib in progressive fibrosing interstitial lung diseases . N Engl J Med 2019. ; 381 ( 18 ): 1718 – 1727 . - PubMed
    1. Ghazipura M , Mammen MJ , Herman DD , et al . Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis . Ann Am Thorac Soc 2022. ; 19 ( 6 ): 1040 – 1049 . - PubMed

MeSH terms